Home > Cluster Organisations > flanders.bio
Printer-friendly versionPrinter-friendly version
General Information
The date when the cluster organisation was established: 
Tuesday, 2 March, 2004
Number of staff in the management team of the cluster organisation : 
6-10
Regions: 
Prov. Oost-Vlaanderen
Membership to other networks/partnerships: 
Cluster Management Team: 
NameSurnamePositionTelephoneEmail
Willem
Dhooge
Cluster Manager
+3292418041
willem.dhooge@flanders.bio
Languages spoken: 
Dutch
English
French
Sectoral and Industrial Focus
Sectoral Industries: 
Agricultural Inputs and Services
Biopharmaceuticals
Technology fields: 
Crop Production
Cellular and Molecular Biology
S3 EU priority areas: 
Biotechnology
Public health and well-being
Emerging industries: 
Biopharmaceuticals
Digital Industries
Areas of specialisation of the cluster not covered above: 
Industrial Biotechnology
Composition of the cluster
Total number of members: 
346
Number of SME members: 
295
Number of larger company members: 
22
Number of research organisations/universities/technology centres: 
17
Number of other ecosystem actors : 
12
Entrepreneurship and scale-up support facilities in the cluster's ecosystem (see "Organisation type"): 
Name and link of major players: 
NameWebsiteType
Ablynx
Larger Company
Galapagos
Larger Company
Janssen Pharmaceutica
Larger Company
VIB
Research Organisation
UCB
Larger Company
GSK
Larger Company
Thrombogenics
SME
Celyad
SME
VITO
Research Organisation
Bone Therapeutics
SME
argenx
SME
imec
Research Organisation
Biocartis
Larger Company
Cochlear
Larger Company
Cluster Strategy
Mission/Objectives: 

flanders.bio strengthens the life sciences ecosystem by facilitating partnering amongst its members. flanders.bio furthermore creates value in the cluster by bringing expertise and a clear strategy to enhance the growth of its members and enabling innovation in healthcare, agricultural production and industrial production through biotechnology via a portfolio of activities and programmes.

Do you have a formalised strategy?: 
Yes
Do you have a specific strategy focus that addresses internationalisation ?: 
Yes
Services
Support services provided: 
Access to private funding (connecting to investors, seed-capital, venture-capital, crowd-funding, etc.)
Access to technology services
Direct advisory services
Facilitation of collaboration between members
Innovation Management / Support of innovation processes (internal, external)
Cooperation Activities
International Cooperation
The main countries targeted by the cluster organisation: 
Japan
United States
Our cluster organisation undertook the following international activities to support our members: 
Participation at missions/events/study visits/fairs
Trans-national Cooperation
The main countries targeted by the cluster organisation: 
Denmark
France
Germany
United Kingdom
Our cluster organisation undertook the following trans-national activities to support our members: 
Support to collaborative activities/etc.
Which clusters do you collaborate with?: 
DSP Valley, Belgium
One Nucleus, UK
Lyon Biopole, France
Bio M, Germany
EuroBiomed, France
BioCat, Spain
Health Holland, the Netherlands
Medicen Paris, France
Support Programmes
Participation in Funded Support Programmes: 
European ProgrammesProject NameName & Description (Regional/National)Link (Regional/National)
CIP/COSME
INTERREG
Other
  • Perso-Med was a collaboration project between FlandersBio and Eurasanté in Lille in the field of Personalised medicine. Personalised or stratified medicine is an innovative treatment concept using molecular profiling technologies for tailoring the right therapeutic strategy for the right person at the right time in terms of effectiveness and safety. The aim of this project was to connect Flemish and French companies active in this innovative field during workshops, seminars and partner matching activities.
  • Nanotech 4 Health is a recently finalised collaboration project, funded by the European Commission through CIP and led by the Flanders Innovation & Entrepreneurship agency with FlandersBio, DSP Valley and FlandersDC as additional partners. Nano4Health had as objective to support the development of innovative healthcare applications at the crossroads of nano-electronics and biotechnology. Integrated and aligned collaboration is a prerequisite to reach this objective. For this reason Nano4Health has developed a systemic and interactive innovation approach –The N4H Fast Track to Innovation- enabling collaboration between stakeholders from different sectors and disciplines on specific, concrete challenges.

IWT, AO and now VLAIO projects (regional Flemish government):

  • XKET4Health is a running collaboration project led by DSP Valley, in collaboration with FlandersBio and 4 representative companies: Ansem, NXP, Biocartis and Cochlear. Project funded by the Flanders Innovation & Entrepreneurship agency, complementary to N4H, aiming at identifying the educational gaps and requirements for a cross-KET innovation approach, aiming at organising a summer school, aiming at developing 3 detailed roadmaps in the cross disciplinary domain (1: advanced medical imaging, including microscope-on-chip and lens-free imaging; 2: lab-on-chip; 3: advanced active implants, including active stimulation and smart pills); aiming at providing support and consultancy for further advancing the 25 projects from N4H to higher TRL’s and to market introduction.
  • Persomed Towers is a running collaboration project led by FlandersBio in collaboration with VIB, (Flemish Research Centre for biotechnology and life sciences), CMI (the centre for medical innovations) and 4 representative companies: Ablynx, Antleron, Biocartis and Janssen Pharmaceutica. Project funded by the Flanders Innovation & Entrepreneurship agency, aiming to lay the foundation for a more efficient and cost effective development of different types of personalised medicine solutions by 1) stimulating collaborations between key stakeholders (patients, patient organisations, government, academia, hospitals, clinical centra and industry) within the Flemish ecosystem, 2) developing a generic collaboration framework within the value chain for co-development of therapeutic and (companion) diagnostic solutions and 3) strategically embed and develop personalised medicine in Flanders and Belgium in order to take a leadership role in Europe.